Orient Pharma (4166.TWO) Earnings Analysis
Orient Pharma (4166.TWO) next reports earnings on 2026-08-19. Trailing P/E 30.30.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does 4166.TWO next report earnings?
| Next earnings date | 2026-08-19 |
|---|---|
| Consensus EPS estimate | n/a |
| Revenue estimate | n/a |
4166.TWO earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-14 | 0.16 TWD | n/a | n/a | n/a |
4166.TWO valuation and analyst view
| Trailing P/E | 30.30 |
|---|---|
| Trailing EPS | 0.80885 TWD |
| Price / book | 2.35 |
| Dividend yield | 0.00% |
| Market cap | 6.37B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Orient Pharma (4166.TWO)'s next earnings date?
Orient Pharma is next scheduled to report on 2026-08-19.
Did 4166.TWO beat earnings last quarter?
Consensus estimate data was not available for 4166.TWO's 2026-05-14 report.
What is 4166.TWO's current P/E ratio and EPS?
4166.TWO trades at a trailing P/E of 30.30 on trailing EPS of 0.8088546917110704 TWD.
What do analysts rate 4166.TWO?
4166.TWO has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.